Drug Utilisation of Mysimba/Contrave (DUS)

October 17, 2023 updated by: Currax Pharmaceuticals

Drug Utilisation and Safety Study of Mysimba in Europe and Contrave in the United States

This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Contrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

43324

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Tennessee
      • Nashville, Tennessee, United States, 37208
        • Currax Pharmaceuticals

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Users of Mysimba/Contrave with at least 365 days of computerized records prior to first use in Denmark Finland, Norway and Sweden, and other countries (if meeting the threshold for patients and agreed upon between EMA and MAH) with sufficient uptake of Mysimba/Contrave in the respective national health systems. Additionally, U.S. data will be included.

Description

Inclusion Criteria:

  • At least one prescription of Mysimba/Contrave in his/her medical records any time during the study period (US) OR at least one dispensing of Mysimba/Contrave in his/her registry any time during the study period (Nordic);
  • At least 365 days of computerized records prior to first Mysimba/Contrave prescription or dispensing date; and3Patient is active (i.e., alive and registered/accruing data) at the time of the first Mysimba/Contrave prescription or dispensing date.

Exclusion Criteria:

- All patients meeting inclusion criteria will be included in the study; no exclusion criteria will be applied.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Demographic characteristics of patients initiating use of Mysimba/Contrave (Age)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Patient demographics (years of age on index date)
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Demographic characteristics of patients initiating use of Mysimba/Contrave (Sex)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Patient demographics (sex [male/female] on index date)
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Demographic characteristics of patients initiating use of Mysimba/Contrave (Race)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Clinically recorded race (i.e., White, Black or African American, Asian, or other/unknown) and ethnicity (i.e., Hispanic or Latino, Non-Hispanic or Latino, or unknown)
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Demographic characteristics of patients initiating use of Mysimba/Contrave (Smoking Status)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Smoking status (i.e., current or ever)
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Demographic characteristics of patients initiating use of Mysimba/Contrave (Comorbidities)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

Existing comorbidities:

  • Metabolic comorbidities (i.e., diabetes or dyslipidemia);
  • Hypertension;
  • Seizure disorder;
  • Hepatic impairment;
  • Central nervous system tumor
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Demographic characteristics of patients initiating use of Mysimba/Contrave (Substance Abuse/Dependencies)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
History of substance abuse/dependencies; including acute opioid withdrawal
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Demographic characteristics of patients initiating use of Mysimba/Contrave (Medical Conditions)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

History of the following medical conditions:

  • Seizures;
  • Bipolar disorder;
  • Major depressive disorder (MDD);
  • Anorexia nervosa;
  • Bulimia;
  • Prior use of naltrexone, bupropion, opioid, or MAOI
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Demographic characteristics of patients initiating use of Mysimba/Contrave (Pregnancy)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Pregnancy status.
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Demographic characteristics of patients initiating use of Mysimba/Contrave (Breastfeeding)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Breastfeeding status.
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Patterns of Mysimba/Contrave initiation (Rx)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Mysimba/Contrave initiation includes number of prescriptions
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Patterns of Mysimba/Contrave initiation (Episodes)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Mysimba/Contrave initiation includes number of treatment episodes
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Patterns of Mysimba/Contrave initiation (Duration)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Mysimba/Contrave initiation includes duration between prescriptions
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Baseline characteristics of patients initiating use of Mysimba/Contrave (Height)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Height (meters) (most recent value on or before the index date)
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Baseline characteristics of patients initiating use of Mysimba/Contrave (Weight)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Weight (kg) (most recent value on or before the index date)
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Baseline characteristics of patients initiating use of Mysimba/Contrave (BMI)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
BMI (kg/m2) (most recent value on or before the index date) (obtained directly from data sources; BMI may be calculated if height and weight available)
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Patterns of Mysimba/Contrave use (Compliance)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Mysimba/Contrave use includes the number and percentage of patients compliant with the SmPC.
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Patterns of Mysimba/Contrave use (Non-compliance)
Time Frame: All available follow-up data up to 548 days after the index date will be included for each patient or end of study period
Mysimba/Contrave use includes the number and percentage of patients non-compliant with the SmPC.
All available follow-up data up to 548 days after the index date will be included for each patient or end of study period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Currax Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2014

Primary Completion (Actual)

October 1, 2022

Study Completion (Actual)

October 1, 2022

Study Registration Dates

First Submitted

October 12, 2023

First Submitted That Met QC Criteria

October 17, 2023

First Posted (Actual)

October 18, 2023

Study Record Updates

Last Update Posted (Actual)

October 18, 2023

Last Update Submitted That Met QC Criteria

October 17, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • NB-451

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe